<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00799968</url>
  </required_header>
  <id_info>
    <org_study_id>2004BA703B07-UK</org_study_id>
    <nct_id>NCT00799968</nct_id>
  </id_info>
  <brief_title>12-h and 2-h Urokinase Regimes of Pulmonary Thromboembolism in China</brief_title>
  <acronym>UKPTEC</acronym>
  <official_title>Efficacy and Safety Evaluation of 12-h and 2-h Urokinase Regimes in the Treatment of Pulmonary Thromboembolism: A Multi-Center, Randomized Controlled Trial in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Chao Yang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparative trials of urokinase (UK) for 12 hours（UK-12h）or 24 hours (UK-24h) have produced
      similar results in acute pulmonary thromboembolism (PTE) thrombolysis. It is unclear whether
      the infusion time can be reduced further. The aim of this study was to investigate the
      efficacy and safety of weight adjusted dosage of UK-2h (20 000 IU/Kg) regime with the Uk-12h
      regime in selected patients with PTE in Chinese population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pulmonary thromboembolism (PTE), a frequent life-threatening complication of deep vein
      thrombosis (DVT), is often underestimated and under diagnosed . Effective early treatment
      will decrease the mortality, reverse right heart dysfunction and reduce risk of chronic
      thromboembolic pulmonary hypertension (CTEPH) or post-thrombotic syndrome (PTS). Thrombolysis
      has proved to be the most rapid and effective therapy to reduce the obstruction of pulmonary
      circulation and normalize hemodynamic parameters. The ultimate goals of thombolytic therapy
      for this disease are to minimize early morbidity and mortality and to prevent recurrence
      without provoking excessive bleeding.

      Currently, the choice of thrombolytic agents and regimens (either UK or rt-PA) is mostly
      based on personal or regional preferences. A loading dose of UK 4400 IU/kg followed by 2200
      IU/kg/hour for 12 hours (UK-12h), or rt-PA 100 mg infusion over 2 hours are recommended for
      acute PTE treatment. However, increasing evidence suggest that UK infusion can be more
      concentrated and time can be further reduced. 100 mg/2 h of rt-PA and a novel dosing regimen
      of UK(3 million U/2 h) had been compared. The results indicated that a 2-h regimen of rt-PA
      and 2h UK exhibited similar efficacy and safety for treatment of acute PTE. UK-2h(20 000U/Kg)
      regimen combined with low molecular weight heparin (LMWH) had been used in Chinese
      population.No severe bleeding and allergic reaction occurred in the thrombolytic group. This
      dosage is much lower than that used by Goldhaber et al, but the efficacy was prominent. Until
      now,no study have been reported to compared UK-2h(20 000U/Kg) regimen with other UK
      regimens(such as UK-12h).

      A relative lower dosage of UK 2-h regimen with body weight adjusted may be an alternative
      choice for treating PTE patients in Chinese population.Considering lower cost and convenience
      of this regimen, the efficacy and safety between UK-2h regimen(20 000U/Kg) and ACCP-approved
      UK-12h regimen for treating acute PTE will be compared.The study is conducted on patients
      with massive PTE with shock or hypotension and/or if without shock or hypotension but with
      right ventricular dysfunction. The clinical efficacy, emboli dissolving efficacy and safety
      will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">February 2006</completion_date>
  <primary_completion_date type="Actual">February 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The improvement of the right ventricular function , perfusion defect score on lung V/Q scans or quantitative computed tomographic pulmonary angiography (CTPA) score.</measure>
    <time_frame>14d</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of major or minor bleeding, death rate, and PTE recurrence at 14d after treatment.</measure>
    <time_frame>14d</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">129</enrollment>
  <condition>Pulmonary Embolism</condition>
  <condition>Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>UK-12h group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UK-2h group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Urokinase</intervention_name>
    <description>UK,bolus 4 400 U/kg followed by intravenous 2 200 U/kg•h for 12 hours</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Urokinase,thrombolytic agent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Urokinase</intervention_name>
    <description>UK,20 000U/kg continuously intravenous infusion for 2 hours</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Urokinase,thrombolytic agent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PTE confirmed either by a high probability ventilation-perfusion lung scanning (V/Q
             scan) or by CTPA.

          -  massive PTE patients with haemodynamic instability and/or cardiogenic shock

          -  Anatomic obstruction more than 2 lobes on CTPA and/or defect more than 7 segments on
             V/Q scan with evidence of right ventricular dysfunction (RVD) and pulmonary
             hypertension on echocardiography

          -  Symptoms within 15 days

          -  Written informed consent was obtained from all the patients before randomization

        Exclusion Criteria:

          -  Received parenteral heparin for more than 72 hours

          -  Known allergic to urokinase

          -  Thrombolytic contraindications such as:

               1. active bleeding or spontaneous intracranial hemorrhage;

               2. major surgery, organ biopsy or recent puncture of a non-compressible vessel less
                  than 10 days;

               3. cerebral arterial thrombosis within 2 months;

               4. gastro-intestinal bleeding within 10 days;

               5. major trauma within the past 15 days;

               6. neurosurgery or ophthalmologic operation with 30 days;

               7. uncontrolled hypertension (systolic blood pressure &gt; 180 mmHg and/or diastolic
                  blood pressure &gt; 110 mmHg);

               8. recent external cardiac resuscitation manoeuvres;

               9. platelet count &lt; 100 000/mm3 at admission;

              10. pregnancy, puerperium or lactation with 2 weeks;

              11. infectious pericarditis or endocarditis;

              12. severe hepatic and kidney dysfunction;

              13. hemorrhagic retinopathy due to diabetes;

              14. a known bleeding disorder.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen WANG, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Institute of Respiratory Medicine,Beijing Chao Yang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Chaoyang Hospital, Capital University of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing General Hospital of the Air-force PLA</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100036</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Fu Xing Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Naval General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Friendship Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100083</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guandong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangzhou Institute of Respiratory Disease，Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shenzhen People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530027</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tangshan Worker's Hospital, Hebei Medical University</name>
      <address>
        <city>Tangshan</city>
        <state>Hebei</state>
        <zip>063000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Hubei Coal University</name>
      <address>
        <city>Tangshan</city>
        <state>Hebei</state>
        <zip>063000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuhan Union Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The General Hospital of Shenyang Military Command</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital Affiliated to Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Medical College Qingdao</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shangdong Yantaishan Hospital</name>
      <address>
        <city>Yantai</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Jining Medical College</name>
      <address>
        <city>Jinan</city>
        <state>Shangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Qingdao University CHENG Zhao-zhong</name>
      <address>
        <city>Qingdao</city>
        <state>Shangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Fifth People's Hospital of Datong in ShanxiWANG;</name>
      <address>
        <city>Datong</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Thoracic Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300051</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xinjiang People's Hospital</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <zip>830001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital, Affiliated with Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Wenzhou Medical College</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Pang BS, Wang C, Lu Y, Yang YH, Xing GH, Mao YL, Huang XX, Zhai ZG. [Changes of blood coagulative and fibrinolytic system and function of pulmonary vascular endothelium after therapy in patients with acute pulmonary thromboembolism]. Zhonghua Yi Xue Za Zhi. 2007 Nov 20;87(43):3074-8. Chinese.</citation>
    <PMID>18261355</PMID>
  </reference>
  <reference>
    <citation>Zhu L, Yang Y, Wu Y, Zhai Z, Wang C. Value of right ventricular dysfunction for prognosis in pulmonary embolism. Int J Cardiol. 2008 Jun 23;127(1):40-5. Epub 2007 Aug 22.</citation>
    <PMID>17716753</PMID>
  </reference>
  <reference>
    <citation>Liu Y, Wang C, Yang Y, Hou X, Wang J. Pro-urokinase up-regulates the expression of urokinase-type plasminogen activator (u-PA) in human pulmonary arterial endothelial cells. Thromb Res. 2008;121(4):485-91. Epub 2007 Jul 20.</citation>
    <PMID>17640719</PMID>
  </reference>
  <reference>
    <citation>Zhu L, Wang C, Yang Y, Wu Y, Zhai Z, Dai H, Pang B, Tong Z. Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism. J Thromb Thrombolysis. 2008 Dec;26(3):251-6. Epub 2007 Aug 21.</citation>
    <PMID>17705052</PMID>
  </reference>
  <reference>
    <citation>Zhu L, Yang YH, Wu YF, Zhai ZG, Wang C; National Project of the Diagnosis and Treatment Strategies for Pulmonary Thromboembolism investigators. Value of transthoracic echocardiography combined with cardiac troponin I in risk stratification in acute pulmonary thromboembolism. Chin Med J (Engl). 2007 Jan 5;120(1):17-21.</citation>
    <PMID>17254482</PMID>
  </reference>
  <reference>
    <citation>Zhai ZG, Wang C, Yang YH, Pang BS, Xiao B, Liu YM, Mao YL, Weng XZ. [Relationship between polymorphisms of plasminogen activator inhibitor-1 promoter gene and pulmonary thromboembolism in Chinese Han population]. Zhonghua Yi Xue Za Zhi. 2006 May 23;86(19):1313-7. Chinese.</citation>
    <PMID>16796899</PMID>
  </reference>
  <reference>
    <citation>Liu CP, Zhang YJ, Lu WX, Ji YQ, Zhang WH, Wang C. [The change of pulmonary surfactant associated protein A in acute pulmonary embolism]. Zhonghua Jie He He Hu Xi Za Zhi. 2005 Sep;28(9):600-3. Chinese.</citation>
    <PMID>16207426</PMID>
  </reference>
  <reference>
    <citation>Ren H, Su PX, Zhang CJ, Gu S, Ma GT, Zhang H, Wang C. [Surgical treatment of chronic pulmonary thromboembolism]. Zhonghua Wai Ke Za Zhi. 2005 Mar 15;43(6):345-7. Chinese.</citation>
    <PMID>15854334</PMID>
  </reference>
  <reference>
    <citation>Wang C, Cheng XS, Zhong NS. [Promoting the clinical and research work on pulmonary thromboembolism in China]. Zhonghua Jie He He Hu Xi Za Zhi. 2004 Nov;27(11):721-2. Chinese.</citation>
    <PMID>15634378</PMID>
  </reference>
  <reference>
    <citation>Pang BS, Wang C, Luo Q, Zhang LM, Zhu M, Mao YL, Huang XX, Guo WJ. [Study of the function of coagulation, fibrinolysis and pulmonary vascular endothelium before and after experimental pulmonary thromboembolism in rabbits]. Zhonghua Jie He He Hu Xi Za Zhi. 2004 Jun;27(6):381-4. Chinese.</citation>
    <PMID>15256085</PMID>
  </reference>
  <reference>
    <citation>Wang F, Wang C, Wang T, Pang BS, Wu YB, Yang YH, Li C, Zhang HY, Weng XZ. [Experimental study of the thrombolytic effects in a canine model of pulmonary thromboembolism induced by autologous radioactive blood clots]. Zhonghua Jie He He Hu Xi Za Zhi. 2004 Feb;27(2):93-6. Chinese.</citation>
    <PMID>14990182</PMID>
  </reference>
  <reference>
    <citation>Zai ZG, Wang C. [Advances in the study of pulmonary thromboembolism]. Zhonghua Jie He He Hu Xi Za Zhi. 2004 Jan;27(1):14-8. Review. Chinese.</citation>
    <PMID>14989818</PMID>
  </reference>
  <reference>
    <citation>Qin ZQ, Wang C. [Comparison of thrombolysis and anticoagulation in pulmonary thromboembolism: a meta-analysis]. Zhonghua Jie He He Hu Xi Za Zhi. 2003 Dec;26(12):772-5. Chinese.</citation>
    <PMID>14720434</PMID>
  </reference>
  <reference>
    <citation>Wang F, Wang C, Wang T, Pang BS, Wu YB, Yang YH, Li C, Zhang HY, Weng XZ. [A canine model of acute pulmonary thromboembolism induced by autologous radioactive blood clots]. Zhonghua Jie He He Hu Xi Za Zhi. 2003 Aug;26(8):470-3. Chinese.</citation>
    <PMID>14505523</PMID>
  </reference>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2008</study_first_submitted>
  <study_first_submitted_qc>November 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2008</study_first_posted>
  <last_update_submitted>November 28, 2008</last_update_submitted>
  <last_update_submitted_qc>November 28, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2008</last_update_posted>
  <responsible_party>
    <name_title>Beijing Chao Yang Hospital</name_title>
    <organization>Chen WANG,Beijing Institute of Respiratory Medicine</organization>
  </responsible_party>
  <keyword>Thrombolytic therapy</keyword>
  <keyword>Urokinase</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrinolytic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

